Cargando…
Iron Chelation Therapy in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload. Iron chelation therapy may be a therapeutic option...
Autores principales: | Messa, Emanuela, Cilloni, Daniela, Saglio, Giuseppe |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905902/ https://www.ncbi.nlm.nih.gov/pubmed/20672005 http://dx.doi.org/10.1155/2010/756289 |
Ejemplares similares
-
Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017) -
Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
por: Parisi, Sarah, et al.
Publicado: (2021) -
Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
por: Gattermann, Norbert
Publicado: (2008) -
Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes
por: Taran, Sachi Jain, et al.
Publicado: (2015) -
Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes
por: Shah, Jayshree, et al.
Publicado: (2016)